Many approaches may help children improve self-regulation

(Reuters Health) – Yoga, exercise, education and personal skills training are among the many types of interventions that may help kids improve what’s known as self-regulation, or their ability to manage their behavior and emotions, a study suggests.

Opioids overprescribed to patients taking certain sedatives

(Reuters Health) – Narcotic painkillers can be particularly dangerous for patients who also take tranquilizing drugs known as benzodiazepines, but a study suggests doctors are still over-prescribing this combination of medicines.

Hungarian laboratory worker isolated after exposure to Ebola virus

BUDAPEST (Reuters) – A Hungarian laboratory worker has been isolated at a Budapest hospital after accidental exposure to the deadly Ebola virus but has shown no symptoms so far, health officials said on Friday.

Many U.S. kids with brain injuries not getting needed rehab

(Reuters Health) – Many children hospitalized in the U.S. for brain injuries don’t receive all the rehabilitation services needed for them to potentially make a full recovery, a new study suggests.

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

BOSTON (Reuters) – Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

Losing a spouse late in life linked to cognitive decline

(Reuters Health) – Older adults who lose a spouse may be more vulnerable to cognitive decline in subsequent years and require extra support and monitoring, researchers say.

Germany’s Merck seeks partners for cancer and immune system drugs

FRANKFURT (Reuters) – Merck KGaA will seek development partners for experimental treatments including tepotinib as the German company looks to licensing deals to help fund clinical trials, according to its head of drug R&D.

Biogen boosts investment in neurology with $1 billion Ionis deal

(Reuters) – U.S. drugmaker Biogen Inc rolled out part of its $37 billion investment warchest on Friday, signing a $1 billion deal that seeks to expand on the strength of an existing partnership with Ionis Pharmaceuticals Inc.

Improving overall heart health may reduce risk of atrial fibrillation

(Reuters Health) – Following practices recommended for “optimal” heart health may also reduce the risk of developing a serious heart-rhythm disorder, researchers say.

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

(Reuters) – An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

WHO recommends testing before use of Sanofi’s dengue vaccine

PARIS/CHICAGO (Reuters) – The World Health Organization (WHO) said on Thursday Sanofi’s vaccine against dengue should only be used after testing on individuals to assess whether they have ever been exposed to the infection.

Large spleen helps explain deep-diving skills of Southeast Asian ‘sea nomads’

(Reuters Health) – An age-old nomadic community of Southeast Asian boat-dwellers who get their food from the sea appear to have evolved enlarged spleens that may help explain their extreme diving prowess, a new study suggests.

Concussion raises Parkinson’s disease risk in large U.S. study

(Reuters Health) – A new study of hundreds of thousands of U.S. armed forces veterans concludes that banging your head severely enough to lose consciousness can dramatically increase the risk of Parkinson’s, the brain disease marked by tremors, slow movements, balance problems and difficulty walking.

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

(Reuters) – An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

Novartis CEO feels heat on U.S. generics, Cosentyx drop

ZURICH (Reuters) – Swiss drugmaker Novartis’ first quarterly results under new CEO Vas Narasimhan have been marred by a prized psoriasis treatment that disappointed and a sharp slump in sales by its U.S. generics unit.

More than half of world’s wealthy expect to live to 100 :survey

LONDON (Reuters) – More than half of wealthy investors around the world expect to live to the age of 100, with almost two in three planning to work longer in life to afford a comfortable retirement, according to a survey on Thursday.

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

(Reuters) – U.S. regulators have expanded use of AstraZeneca’s lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

AI pharma firm BenevolentAI raises $115 million in funding

LONDON (Reuters) – BenevolentAI, a British pharmaceutical company that uses artificial intelligence to identify new drug candidates, said it had raised $115 million in a funding round that valued it at $2 billion. 

Experts query case for GlaxoSmithKline’s new 3-in-1 lung drug

LONDON (Reuters) – Two medical experts have urged caution in using a new three-in-one inhaler for chronic lung disease from GlaxoSmithKline, which the company hopes will help it keep its lead in respiratory medicine despite rising competition.

Later middle school start times tied to longer sleep for kids

(Reuters Health) – Starting middle school classes after 8 a.m. could help pre-teens get more sleep and be more awake during their morning lessons, a U.S. study suggests.

Gates backs gene technologies in fight to end malaria

LONDON, April 18 (Reuters) – Gene-editing technologies that alter mosquitoes’ DNA could prove critical in the fight against malaria, Bill Gates said on Wednesday, and ethical concerns should not block progress in such gene-modifying research.

Tooth loss in middle age linked to heart disease

(Reuters Health) – Losing two or more natural teeth in middle age may signal an increased risk for coronary heart disease, a U.S. study suggests.

Cleaned endoscopes often contaminated

Many patients may be undergoing endoscopy with contaminated instruments, a pair of new studies suggest.

Raising retirement age may hit least-educated workers hardest

Reuters Health – People with little education and low socioeconomic status are more likely to leave the workforce in midlife for health reasons than better educated and higher-status workers, suggests a review of research across four developed countries.

Kentucky accuses J&J of contributing to opioid epidemic

(Reuters) – Kentucky’s attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction.

GSK flags pharma M&A ambitions by poaching Roche deal-maker

LONDON (Reuters) – GlaxoSmithKline signaled its intention to boost its drug pipeline through deals on Wednesday by hiring Kevin Sin from Roche’s Genentech unit to lead a worldwide search for promising experimental products.

Industry fears disruption as EU excludes UK from drug approvals

LONDON (Reuters) – A European decision to exclude Britain from the EU’s drug approval system from March 30 2019 – the day after Brexit – has raised alarm among drugmakers, who fear the abrupt change could disrupt medicine supplies to patients.

Novo Nordisk, Red Cross team up to tackle chronic diseases in conflict zones

COPENHAGEN (Reuters) – Danish drugmaker Novo Nordisk and aid agency Red Cross have teamed up to try to improve the treatment of chronic diseases among the millions affected by conflicts and humanitarian crises in countries such as Syria and Yemen.

Canada seeks U.S. help to solve EpiPen shortage

TORONTO (Reuters) – Canada said on Tuesday it is working with the U.S. Food and Drug Administration to access supplies of Mylan N.V.’s EpiPen emergency allergy antidote amid a growing shortage that has spared the United States.

Global leaders seek to reignite fight against deadly malaria

LONDON, April 18 (Reuters) – Renewed action and boosted funding to fight malaria could prevent 350 million cases of the disease in the next five years and save 650,000 lives across commonwealth countries, health experts said on Wednesday.